Fresenius Medical Care AG has announced the official launch of its 6008 CARESystem hemodialysis filtration system in China, marking a significant advancement in the treatment options for patients with renal failure in the country.
The 6008 CARESystem is comprised of a 6008 blood dialysis device and a complementary 6008 CARESet blood purification extracorporeal circulation system. This system has been subject to rigorous evaluation through the global, randomized, large-scale controlled study known as CONVINCE. The study demonstrated that patients undergoing high-volume hemodialysis with the 6008 CARESystem experienced a lower risk of mortality compared to those receiving standard high-volume hemodialysis, with a notable 23% reduction in risk.- Flcube.com
